预留授予第一个归属期归属条件成就的公告 证券代码：301033 证券简称：迈普医学 公告编号：2025-044 广州迈普再生医学科技股份有限公司 本公司及董事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 重要内容提示： 1、本次符合归属条件的预留授予部分激励对象人数：3 人； 2、本次拟归属的预留授予部分限制性股票数量：44,498 股，占 公司总股本（剔除回购股份，下同）0.07%； 广州迈普再生医学科技股份有限公司（以下简称"公司"）于 2025 年 7 月 7 日召开第三届董事会第十一次会议，审议通过了《关于 2023 3、本次拟归属的预留授予部分限制性股票授予价格：19.80 元/ 股（调整后）； 4、本次拟归属的预留授予部分限制性股票来源：公司向激励对 象定向发行的本公司人民币 A 股普通股股票； 5、本次拟归属的预留授予部分限制性股票在相关手续办理完成 后、上市流通前，公司将发布相关提示性公告，敬请投资者关注。 关于 2023 年限制性股票激励计划 预留授予部分第一个归属期归属条件成就的公告 本激励计划涉及的标的股票来源为公司向激励对象定向发行的 本公司人民 ...

Group 1 - The company plans to acquire 100% equity of Guangzhou Yijie Medical Technology Co., Ltd. through a combination of issuing shares and cash payment, while also raising supporting funds [1][2] - The transaction is expected not to constitute a major asset reorganization but is classified as a related party transaction, which does not qualify as a reorganization listing [1] - The company has been actively promoting the transaction since the disclosure of the preliminary plan, and is currently cooperating with intermediaries to conduct due diligence, auditing, and evaluation [2][3] Group 2 - The company’s stock was suspended from trading on May 22, 2025, due to the planning of this transaction, and resumed trading on June 6, 2025 [2] - The board of directors and the supervisory board have approved the transaction plan and its summary during meetings held on June 5, 2025 [2] - The company will adhere to relevant laws and regulations regarding major asset restructuring and will fulfill its information disclosure obligations in a timely manner [3][4]

Mergers and Acquisitions - Aladdin announced its participation in the auction for 81.96% equity of Kasma Holdings, with a transfer base price of 202 million yuan, aiming to expand sales channels and integrate downstream resources [1] - *ST Baoshi received approval from the Ningxia State-owned Assets Supervision and Administration Commission for the acquisition of 100% equity of Ningxia Electric Power Investment New Energy Co., Ltd. through major asset replacement and cash payment [2] - Guotou Zhonglu disclosed a transaction plan to acquire 100% shares of China Electronic Engineering Design Institute through share issuance, with the specific transaction price yet to be determined [3] Shareholding Changes - MaiPu Medical announced that shareholder Tang Ying plans to reduce holdings by no more than 1% of the company's shares, totaling up to 665,100 shares [4] - Yue Wannianqing disclosed that a 10% shareholder, Hehe Investment, plans to reduce holdings by no more than 6% of the company's shares, totaling up to 4.8 million shares [5] - *ST Huawang announced that shareholder Wu Qun plans to reduce holdings by no more than 1.76% of the company's shares, totaling up to 15,414,300 shares [6] Regulatory Issues - Liuhua Co. received an administrative regulatory decision from the Guangxi Securities Regulatory Bureau due to issues related to accounting irregularities and failure to fulfill obligations regarding the integrity of appointed directors and supervisors [7] - *ST Huike was investigated by the China Securities Regulatory Commission for suspected violations of information disclosure laws [8][9] - Tuisijingang announced that two vice presidents were arrested for violating important information disclosure laws, but stated that this would not impact the company's normal operations [10]

Key Points - The article summarizes important announcements from various listed companies in the Shanghai and Shenzhen stock markets on July 4, providing insights for investors [2] Group 1: Major Corporate Actions - China Shipbuilding Industry Corporation's absorption and merger with China Shipbuilding Industry Group has been approved by the Shanghai Stock Exchange, pending further regulatory approvals [3] - Aerospace Hongtu's controlling shareholder's action party plans to transfer 5.1% of the company's shares to a private equity fund at a price of 19 yuan per share, totaling 253 million yuan [4] - Guotou Zhonglu plans to acquire 100% of China Electronic Engineering Design Institute through a share issuance, with the transaction price yet to be determined [5] - Haitai Development intends to transfer 100% of its subsidiary's equity for 90.6595 million yuan, aiming to optimize its asset structure [6] - Gensun Bio plans to invest approximately 150 million yuan to build an intelligent production and R&D base, expected to be completed by 2028 [7] - Xinhua Insurance intends to invest 11.25 billion yuan to subscribe to a private equity fund, which has a total size of 22.5 billion yuan [8] - Huaming Equipment has raised its share repurchase fund limit from 200 million yuan to 250 million yuan [9] - Aotewei's controlling shareholders plan to transfer 4.99% of the company's shares through a pricing inquiry [10] - Jianke Institute plans to publicly transfer 40% of its stake in Hubei Jiansheng Engineering Technology Consulting Co., Ltd. [11] - Aerospace Electronics plans to increase capital in its subsidiary to enhance its capabilities in unmanned systems [12] Group 2: Financial Performance - Jin Xin Nong reported a 1.23% year-on-year decline in pig sales revenue for the first half of 2025, totaling 763 million yuan [14] - Tianbang Food's June pig sales revenue decreased by 4.01% month-on-month, with a total of 4.143 billion yuan for the first half of 2025 [15] - GAC Group's June automobile sales fell by 8.22% year-on-year, with a total of 755,300 vehicles sold in the first half of 2025, down 12.48% [16] - Pulite expects a net profit increase of 38.88% to 66.65% for the first half of 2025, driven by growth in modified materials and new energy businesses [18] - Zhuye Group anticipates a net profit increase of 50.97% to 75.23% for the first half of 2025, benefiting from rising precious metal prices [19] - Xindong Lian Ke expects a net profit increase of 144.46% to 199.37% for the first half of 2025, supported by sufficient orders and revenue growth [20] - Zhongce Rubber forecasts a net profit decrease of 6.3% to 11.81% for the first half of 2025, due to a one-time gain in the previous year [21] - *ST Sihua expects a net loss of 11 million to 17 million yuan for the first half of 2025, despite significant sales order growth [22] - Sankeshu anticipates a net profit increase of 80.94% to 119.04% for the first half of 2025, driven by growth in retail business and improved gross margins [23] Group 3: Major Contracts and Shareholding Changes - Hongsheng Huayuan's subsidiary is expected to win a bid for a project worth approximately 1.127 billion yuan from the Southern Power Grid [25] - Times New Materials signed contracts worth approximately 2.711 billion yuan for wind turbine blade sales in the second quarter of 2025 [26] - Guojian Group's controlling shareholder reduced its holdings of convertible bonds by 900,000 units, accounting for 11.25% of the total issuance [27] - Yue Wanniang's controlling shareholder plans to reduce its stake by up to 6% through various trading methods [28] - Maipu Medical's shareholder plans to reduce its stake by up to 665,100 shares, representing 0.9999% of the total shares [29] - Jiulian Technology's directors and senior management plan to reduce their holdings by up to 2.61% of the total shares [30] - *ST Huawang's shareholder plans to reduce its stake by up to 1.76% through trading methods [32]

预披露公告 公司股东唐莹女士保证向本公司提供的信息内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 特别提示： 1、截至本公告披露日，公司股东唐莹女士及其一致行动人叶涛先生合计持 有公司股份 2,975,977 股，占总股本的 4.4738%（占剔除公司回购专用证券账户 股份数量后总股本的 4.4977%）。 2、因个人资金需要，唐莹女士计划通过集中竞价交易方式减持公司股份不 超过 665,100 股，占公司总股本的 0.9999%（占剔除公司回购专用证券账户股份 数量后总股本的 1.0052%），减持期间为自本公告披露之日起 15 个交易日后的 3 个月内。 3、唐莹女士承诺，在任意连续九十个自然日内，减持股份的总数不得超过 公司股份总数的百分之一。 公司于近日收到公司股东唐莹女士出具的《关于计划减持股份的 告知函》，现将有关情况公告如下： 证券代码：301033 证券简称：迈普医学 公告编号：2025-042 广州迈普再生医学科技股份有限公司 关于公司股东减持股份的预披露公告 一、 减持主体的基本情况 | 股东名称 | 股东身 ...

进展公告 证券代码：301033 证券简称：迈普医学 公告编号：2025-041 广州迈普再生医学科技股份有限公司 关于发行股份及支付现金购买资产并募集配套资金 暨关联交易事项的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 重要风险提示： 1、广州迈普再生医学科技股份有限公司（以下简称"公司"）于 2025 年 6 月 6 日披露了《广州迈普再生医学科技股份有限公司发行股份及支付现金购买资 产并募集配套资金暨关联交易预案》（以下简称"重组预案"）及其摘要，并对 本次交易涉及的有关风险因素及尚需履行的审批程序进行了详细说明，提请广大 投资者关注后续进展公告并注意投资风险。 2、截至本公告披露日，除重组预案中披露的有关风险因素外，公司尚未发 现可能导致公司董事会或者交易对方撤销、中止本次交易或者对本次交易方案作 出实质性变更的相关事项，本次交易相关工作正在有序推进中。公司将根据相关 事项的进展情况及时履行信息披露义务。 一、本次交易概述 公司拟通过发行股份及支付现金的方式向泽新医疗等 10 名交易 对方购买广州易介医疗科技有限公司（以下简称"易介医疗" ...

Industry Overview - The hard brain (spinal) membrane patch is a sheet-like material used for temporary or permanent repair of defects in the dura mater and/or spinal dura mater [1] - The demand for hard brain (spinal) membrane patches is increasing due to the aging population, rising incidence of cerebrovascular diseases, and improved disease awareness among the public [1][8] - The market size for hard brain (spinal) membrane patches in China is projected to reach 1.18 billion yuan in 2024 and 1.841 billion yuan by 2029 [1][8] Market Status - The artificial hard brain (spinal) membrane patch is primarily used to fill local losses or defects in the dura mater, which is crucial for protecting brain tissue [6] - Since 2020, hard brain (spinal) membrane patches have been included in bulk procurement across 24 provinces in China, leading to significant price reductions, with average price drops of 70%-90% in several provinces [6][8] - The market size for hard brain (spinal) membrane patches had previously expanded significantly from 2016 to 2020 but faced a contraction due to centralized procurement policies [8] Key Enterprises - Major companies in the hard brain (spinal) membrane patch industry include Guanhao Biological, Zhenghai Biological, Maipu Medical, and Bairen Medical, among others [2][12] - Guanhao Biological reported a total revenue of 377 million yuan in 2024, with a year-on-year decline of 6.6% [13] - Zhenghai Biological's revenue for 2024 was 363 million yuan, down 12.19% year-on-year, with its membrane series products generating 149 million yuan [15] Development Trends - Technological innovations such as 3D printing, nanofiber materials, and bioactive composite materials are being increasingly applied in the development and production of hard brain (spinal) membrane patches [17] - The domestic production rate of artificial hard brain (spinal) membrane patches has reached 90%, with companies like Maipu Medical and Guanhao Biological enhancing their technological capabilities [18] - Government policies supporting the medical device industry and stricter regulations are creating a favorable environment for the development of the hard brain (spinal) membrane patch industry [19]

Company Overview - Mypu Medical is a technology-driven enterprise focused on high-performance implantable medical devices, specifically in the neurosurgery field, and is one of the few domestic companies entering the global high-end market [3][4]. Market Insights - The global market for absorbable hemostatic materials was valued at approximately CNY 20.2 billion in 2020 and increased to CNY 21.9 billion in 2021 [3]. - The terminal market for dural sealing materials in China was about CNY 2.275 billion in 2020 [3]. Technology Platforms - Mypu Medical has developed four major technology platforms: - **Bioprinting Technology**: Used to create artificial dura mater and absorbable repair membranes [4]. - **Digital Design and Precision Processing**: Enables high compatibility for cranial defect repair products using PEEK materials [4]. - **Selective Oxidation and Microfiber Network Formation**: Focused on high-performance hemostatic products for neurosurgery, breaking the long-standing import monopoly [4]. - **Multicomponent Crosslinking and Gel Technology**: Developed dural adhesive products with low swelling and neutral pH, addressing sealing effectiveness and clinical application risks [4]. Product Development - The dural adhesive product received domestic NMPA registration in February 2023 and is expected to obtain EU CE certification by March 2025, with ongoing sales efforts in domestic and international markets [4][5]. - The absorbable regenerated oxidized cellulose hemostatic product is one of the few successfully industrialized products in China, demonstrating effective hemostatic capabilities [5]. Strategic Focus - Mypu Medical aims to strengthen core capabilities and seize opportunities to enhance operational efficiency, targeting improved performance in 2025 [6]. - The company is actively monitoring and participating in centralized procurement projects to leverage national and local procurement opportunities [6].

Core Viewpoint - The healthcare services sector experienced a decline of 1.45% with a net outflow of 1,102.31 million in funds, indicating a bearish trend in the market [1] Group 1: Sector Performance - The healthcare services sector saw a total of 2 stocks rising and 41 stocks declining [1] - The top ten decliners in the sector included Sanbo Brain Science (-4.57%), Ruizhi Medicine (-4.56%), and Innovation Medical (-4.34%) [1] Group 2: Stock Details - Sanbo Brain Science closed at 49.87 with a decline of 4.57% and a net fund outflow of 108.09 million [1] - Ruizhi Medicine closed at 10.88, down 4.56%, with a net outflow of 68.69 million [1] - Innovation Medical closed at 15.00, down 4.34%, with a net outflow of 320.40 million [1] - Other notable decliners included Maipu Medical (-3.79%), Nuotai Biological (-3.40%), and Dae Oriental (-3.21%) [1] Group 3: Gainers - The stocks that gained included *ST Biological with an increase of 3.83% and Chengda Pharmaceutical with an increase of 1.03% [1]

Core Viewpoint - The announcement details the planned share reduction by GuoShou ChengDa, a pre-IPO shareholder of Guangzhou MaiPu Medical Technology Co., Ltd, indicating a reduction of up to 1,995,582 shares, which represents 3% of the company's total share capital [2][3][4]. Group 1: Shareholder Information - GuoShou ChengDa holds 3,267,436 shares, accounting for 4.9120% of the total share capital, and 4.9382% when excluding shares held in the company's repurchase account [2][4]. - The shares held by GuoShou ChengDa were acquired prior to the company's initial public offering and were released from lock-up on July 26, 2022 [3][4]. Group 2: Reduction Plan Details - The reason for the share reduction is stated as operational needs [4]. - The planned reduction includes a maximum of 1,995,582 shares, with 1,330,388 shares to be sold through block trading and the remainder through centralized bidding [3][4]. - The reduction period will commence 15 trading days after the announcement and will last for three months, subject to market conditions [4][6]. Group 3: Compliance and Commitments - GuoShou ChengDa has committed to adhere to legal regulations and the company's internal policies regarding shareholding and reduction [6][7]. - The shareholder has not violated any commitments made during the IPO process and will ensure compliance with all relevant laws during the reduction period [7][8].